RenovoRx, Inc. (RNXT) Stock Forecast
RNXT analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 4 analysts
- Price target
- $7.12 average of analyst targets
- Upside to target
- +525.0% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.05
- 52-week range
- $0.73 – $2.52
RNXT analyst ratings
4 analystsNumber of analysts at each rating.
RNXT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
RNXT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.05 | −$0.07 | −$0.03 | −$0.08 | +37.5% | 2 |
| Current fiscal year (2026) | −$0.27 | −$0.27 | −$0.27 | −$0.32 | +15.6% | 1 |
| Next fiscal year (2027) | −$0.12 | −$0.20 | −$0.04 | −$0.27 | +55.6% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
RNXT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.1M | $1.0M | $1.1M | +300.2% | 4 |
| Current fiscal year (2026) | $3.9M | $3.7M | $4.0M | +244.8% | 4 |
| Next fiscal year (2027) | $11.4M | $10.0M | $14.0M | +195.3% | 4 |
RNXT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
RNXT revenue: reported and forecast
RNXT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.08 | −$0.07 | −$0.07 | −$0.03 | −$0.05 | −37.5% | 0 up · 0 down |
| Current fiscal year (2026) | −$0.33 | −$0.31 | −$0.31 | −$0.29 | −$0.27 | −18.2% | 1 up · 0 down |
| Next fiscal year (2027) | −$0.13 | −$0.15 | −$0.15 | −$0.15 | −$0.12 | −7.7% | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
RNXT earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; RNXT beat in 11 of 12.
What analysts expect from RNXT
4 analysts cover RenovoRx; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $7.12, 525.0% above the latest close of $1.14. Analysts expect earnings of −$0.27 per share for 2026, +15.6% from a year earlier. For 2027 the average estimate is −$0.12 per share on revenue of $11.4 million. RenovoRx beat the EPS estimate in 11 of the last 12 quarters.
Related: RNXT income statement, RNXT key metrics, RNXT chart. See the RNXT stock overview for the latest quote and news.
RNXT forecast FAQ
What is RenovoRx's price target?
The average analyst price target for RenovoRx is $7.12, 525.0% above the latest close of $1.14.
Is RenovoRx a buy, hold or sell?
Of 4 analysts covering RenovoRx, 4 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is RenovoRx's EPS forecast?
Analysts forecast −$0.27 per share for 2026 (range −$0.27 to −$0.27); for 2027 the estimate is −$0.12.
What is RenovoRx's revenue forecast?
The average revenue estimate for 2026 is $3.9 million, growth of 244.8%; for 2027 it is $11.4 million.
When does RenovoRx report earnings?
RenovoRx is expected to report results for the quarter ending September 30, 2026 on November 12, 2026; the EPS estimate is $-0.05.
Does RenovoRx usually beat earnings estimates?
RenovoRx reported EPS at or above the analyst estimate in 11 of the last 12 quarters.